Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cohen & Steers, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to institutional investors, including pension funds, endowments, and foundations. It manages separate client-focused equity, fixed income, multi-asset, and commodity portfolios through its subsidiaries. The firm launches and manages equity, fixed income, balanced, and multi-asset mutual funds through its subsidiaries. Through its subsidiaries, it also launches and manages hedge funds. The firm invests in public equity, fixed income, and commodity markets across the globe through its subsidiaries. Through its subsidiaries, it invests in companies operating in the real estate sector, including real estate investment trusts, infrastructure sector, and natural energy resources sector for its equity and fixed income investments. The firm also invests in preferred securities for its fixed income investments through its subsidiaries. Cohen & Steers, Inc. was founded in 1986 and is based in New York, with additional offices in London, United Kingdom; Central, Hong Kong; Tokyo, Japan; and Seattle, Washington.

Cohen & Steers, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, MAY 8, 2026 /PRNEWSWIRE/ -- COHEN & STEERS, INC. (NYSE:CNS) ANNOUNCED TODAY PENDING CHANGES TO ITS GLOBAL REALTY MAJORS PORTFOLIO INDEX (GRM) AND INTERNATIONAL REALTY MAJORS PORTFOLIO INDEX (IRP), EFFECTIVE AS OF THE CLOSE OF BUSINESS ON MAY 15, 2026. COHEN & STEERS GLOBAL REALTY MAJORS PORTFOLIO INDEX (GRM) ADDED COMPONENT (SYMBOL) REMOVED COMPONENT (SYMBOL) AZRIELI GROUP LTD.

COHEN & STEERS ANNOUNCES CHANGES TO REALTY INDEXES

PLENARY SESSION AT AANS UNDERSCORES REYOBIQ'S POTENTIAL AS A DIFFERENTIATED TARGETED RADIOTHERAPEUTIC PLATFORM FOR CNS CANCERS PLENARY SESSION AT AANS UNDERSCORES REYOBIQ'S POTENTIAL AS A DIFFERENTIATED TARGETED RADIOTHERAPEUTIC PLATFORM FOR CNS CANCERS

PLUS THERAPEUTICS ANNOUNCES ORAL PRESENTATION HIGHLIGHTING REYOBIQ CLINICAL AND TRANSLATIONAL DATA DEMONSTRATING FAVORABLE SAFETY, SURVIVAL, AND EMERGING IMMUNOMODULATION IN LEPTOMENINGEAL METASTASES

AGOURA HILLS, CALIF., MAY 06, 2026 (GLOBE NEWSWIRE) -- VIA IBN -- ONCOTELIC THERAPEUTICS, INC. (OTCQB: OTLC) (ONCOTELIC OR THE COMPANY), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON ONCOLOGY AND RARE DISEASES, TODAY ANNOUNCED THE CONSUMMATION OF A STRATEGIC ASSET TRANSFER AGREEMENT WITH LUNAI BIOWORKS, INC. (LNAI) FOR ITS N2B (NOSE-TO-BRAIN) DELIVERY SYSTEM, ESTABLISHING AN INITIATIVE ON BIODEFENSE AND ALZHEIMER'S DISEASE (AD). IN RETURN, ONCOTELIC RECEIVED $12.5 MILLION IN LUNAI BIOWORKS SERIES B CONVERTIBLE PREFERRED STOCK. THE COMPANY CONTINUES TO EVALUATE ADDITIONAL PARTNERSHIPS TO FURTHER MONETIZE ITS PORTFOLIO WHILE MAINTAINING STRATEGIC CONTROL OVER CORE ASSETS.

ONCOTELIC THERAPEUTICS ANNOUNCES CLOSING OF A STRATEGIC MONETIZATION OF ITS CNS/NASAL ASSETS WITH LUNAI BIOWORKS, ADVANCING JOINT DEVELOPMENT IN BIODEFENSE AND ALZHEIMER'S DISEASE

TRANSACTION ADDS DUAL BBB DELIVERY STRATEGIES, SUPPORTS ALZHEIMER'S PROGRAMS, COMBINATION THERAPIES, 505(B)(2) PATHWAYS, AND CNS COUNTERMEASURE APPLICATIONS SACRAMENTO, CALIF., MAY 4, 2026 /PRNEWSWIRE/ -- LUNAIBIOWORKS, INC. (NASDAQ: LNAI) TODAY ANNOUNCED THE COMPLETION OF A $20 MILLION PREFERRED EQUITY ISSUANCE TO ACQUIRE INTELLECTUAL PROPERTY ASSETS FROM TWO COUNTERPARTIES, EXPANDING THE COMPANY'S CENTRAL NERVOUS SYSTEM (CNS) PLATFORM WITH COMPLEMENTARY NEUROTHERAPEUTIC COMPOUNDS AND DELIVERY TECHNOLOGIES.

LUNAI BIOWORKS COMPLETES $20 MILLION PREFERRED ISSUANCE TO ACQUIRE CNS DELIVERY AND NEUROTHERAPEUTIC IP

THE PRIVATE PLACEMENT INCLUDES PARTICIPATION FROM SEVERAL LEADING HEALTHCARE INVESTORS INCLUDING ADAR1 CAPITAL, IKARIAN CAPITAL, STONEPINE CAPITAL MANAGEMENT AND NAZARE PARTNERS PROCEEDS EXPECTED TO ENABLE CNS PHARMACEUTICALS TO ACQUIRE DIFFERENTIATED, CLINICAL-STAGE ASSETS WITH IDENTIFIABLE NEAR-TERM VALUE-INFLECTION CATALYSTS, ALIGNED WITH ITS RECENTLY ANNOUNCED CORPORATE STRATEGY HOUSTON, TX / ACCESS NEWSWIRE / MAY 4, 2026 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOTECHNOLOGY COMPANY FOCUSED ON BUILDING A PIPELINE OF INNOVATIVE THERAPIES ADDRESSING SIGNIFICANT UNMET MEDICAL NEEDS, ANNOUNCED TODAY THAT IT HAS ENTERED INTO SECURITIES PURCHASE AGREEMENTS FOR A PRIVATE PLACEMENT FINANCING THAT IS EXPECTED TO RESULT IN GROSS PROCEEDS OF APPROXIMATELY $22.5 MILLION TO THE COMPANY, BEFORE PLACEMENT AGENT FEES AND OFFERING EXPENSES. THE PRIVATE PLACEMENT INCLUDES PARTICIPATION FROM INSTITUTIONAL HEALTHCARE INVESTORS, INCLUDING ADAR1 CAPITAL, IKARIAN CAPITAL, STONEPINE CAPITAL MANAGEMENT AND NAZARE PARTNERS.

CNS PHARMACEUTICALS ANNOUNCES OVERSUBSCRIBED $22.5 MILLION PRIVATE PLACEMENT FINANCING

NEW YORK, APRIL 30, 2026 /PRNEWSWIRE/ -- THE BOARD OF DIRECTORS OF COHEN & STEERS, INC. (NYSE: CNS) DECLARED A CASH DIVIDEND FOR THE SECOND QUARTER OF 2026 IN THE AMOUNT OF $0.67 PER SHARE OF COMMON STOCK PAYABLE ON MAY 21, 2026 TO STOCKHOLDERS OF RECORD AS OF THE CLOSE OF BUSINESS ON MAY 11, 2026. ABOUT COHEN & STEERS.

COHEN & STEERS, INC. DECLARES QUARTERLY DIVIDEND

NEW YORK, APRIL 29, 2026 /PRNEWSWIRE/ -- THIS PRESS RELEASE PROVIDES SHAREHOLDERS OF COHEN & STEERS QUALITY INCOME REALTY FUND, INC. (NYSE: RQI) (THE "FUND") WITH INFORMATION REGARDING THE SOURCES OF THE DISTRIBUTION TO BE PAID ON APRIL 30, 2026 AND CUMULATIVE DISTRIBUTIONS PAID FISCAL YEAR-TO-DATE. IN DECEMBER 2012, THE FUND IMPLEMENTED A MANAGED DISTRIBUTION POLICY IN ACCORDANCE WITH EXEMPTIVE RELIEF ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.

COHEN & STEERS QUALITY INCOME REALTY FUND, INC. (RQI) NOTIFICATION OF SOURCES OF DISTRIBUTION UNDER SECTION 19(A)

NEW YORK, APRIL 29, 2026 /PRNEWSWIRE/ -- THIS PRESS RELEASE PROVIDES SHAREHOLDERS OF COHEN & STEERS INFRASTRUCTURE FUND, INC. (NYSE: UTF) (THE "FUND") WITH INFORMATION REGARDING THE SOURCES OF THE DISTRIBUTION TO BE PAID ON APRIL 30, 2026 AND CUMULATIVE DISTRIBUTIONS PAID FISCAL YEAR-TO-DATE. IN MARCH 2015, THE FUND IMPLEMENTED A MANAGED DISTRIBUTION POLICY IN ACCORDANCE WITH EXEMPTIVE RELIEF ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.

COHEN & STEERS INFRASTRUCTURE FUND, INC. (UTF) NOTIFICATION OF SOURCES OF DISTRIBUTION UNDER SECTION 19(A)

NEW YORK, APRIL 29, 2026 /PRNEWSWIRE/ -- THIS PRESS RELEASE PROVIDES SHAREHOLDERS OF COHEN & STEERSREIT AND PREFERRED AND INCOME FUND, INC. (NYSE:RNP) (THE "FUND") WITH INFORMATION REGARDING THE SOURCES OF THE DISTRIBUTION TO BE PAID ON APRIL 30, 2026 AND CUMULATIVE DISTRIBUTIONS PAID FISCAL YEAR-TO-DATE. IN DECEMBER 2017, THE FUND IMPLEMENTED A MANAGED DISTRIBUTION POLICY IN ACCORDANCE WITH EXEMPTIVE RELIEF ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.

COHEN & STEERS REIT AND PREFERRED AND INCOME FUND, INC. (RNP) NOTIFICATION OF SOURCES OF DISTRIBUTION UNDER SECTION 19(A)

NEW YORK, APRIL 29, 2026 /PRNEWSWIRE/ -- THIS PRESS RELEASE PROVIDES SHAREHOLDERS OF COHEN & STEERS TOTAL RETURN REALTY FUND, INC. (NYSE: RFI) (THE "FUND") WITH INFORMATION REGARDING THE SOURCES OF THE DISTRIBUTION TO BE PAID ON APRIL 30, 2026 AND CUMULATIVE DISTRIBUTIONS PAID FISCAL YEAR-TO-DATE. IN DECEMBER 2011, THE FUND IMPLEMENTED A MANAGED DISTRIBUTION POLICY IN ACCORDANCE WITH EXEMPTIVE RELIEF ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.

COHEN & STEERS TOTAL RETURN REALTY FUND, INC. (RFI) NOTIFICATION OF SOURCES OF DISTRIBUTION UNDER SECTION 19(A)

NEW YORK, APRIL 29, 2026 /PRNEWSWIRE/ -- THIS PRESS RELEASE PROVIDES SHAREHOLDERS OF COHEN & STEERS CLOSED-END OPPORTUNITY FUND, INC. (NYSE: FOF) (THE "FUND") WITH INFORMATION REGARDING THE SOURCES OF THE DISTRIBUTION TO BE PAID ON APRIL 30, 2026 AND CUMULATIVE DISTRIBUTIONS PAID FISCAL YEAR-TO-DATE. IN DECEMBER 2021, THE FUND IMPLEMENTED A MANAGED DISTRIBUTION POLICY IN ACCORDANCE WITH EXEMPTIVE RELIEF ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.

COHEN & STEERS CLOSED-END OPPORTUNITY FUND, INC. (FOF) NOTIFICATION OF SOURCES OF DISTRIBUTION UNDER SECTION 19(A)

EXPANDS ACCESS BY 6 MILLION COVERED LIVES, ADVANCING COMMERCIAL MOMENTUM FOR CNSIDE IN METASTATIC CNS CANCERS EXPANDS ACCESS BY 6 MILLION COVERED LIVES, ADVANCING COMMERCIAL MOMENTUM FOR CNSIDE IN METASTATIC CNS CANCERS

PLUS THERAPEUTICS SECURES BLUE SHIELD OF CALIFORNIA COVERAGE FOR CNSIDE CEREBROSPINAL FLUID ASSAY FOR METASTATIC CNS CANCER

- DATA UNDERSCORE THE DIFFERENTIATED CAPABILITY OF THE CLINICALLY VALIDATED FORCE PLATFORM TO CROSS THE BLOOD-BRAIN BARRIER -

DYNE THERAPEUTICS ANNOUNCES UPCOMING PRESENTATION HIGHLIGHTING ROBUST CNS ACTIVITY IN NONHUMAN PRIMATES WITH ITS FORCE PLATFORM AT 2026 ASGCT ANNUAL MEETING

- LATE-BREAKING ORAL PRESENTATION: IV DELIVERY OF VY1706, A CNS PENETRANT AAV GENE THERAPY FOR AD, DEMONSTRATES COMPELLING PHARMACOLOGY AND SAFETY IN A 3-MONTH GLP TOXICOLOGY STUDY IN NHPS -

VOYAGER IV-DELIVERED CNS GENE THERAPIES FEATURED IN MULTIPLE PRESENTATIONS AT ASGCT 2026, INCLUDING LATE BREAKER ON TAU-TARGETED VY1706 FOR ALZHEIMER'S DISEASE

BRIAN W. HELLER TO SUCCEED MR. POLI IN 2027 NEW YORK, APRIL 27, 2026 /PRNEWSWIRE/ -- COHEN & STEERS, INC. (NYSE: CNS) TODAY ANNOUNCED THAT FRANCIS C.

COHEN & STEERS ANNOUNCES THE RETIREMENT OF FRANCIS C. POLI, GENERAL COUNSEL & CORPORATE SECRETARY

NYSE ISSUES A PRE-MARKET DAILY ADVISORY DIRECT FROM THE TRADING FLOOR. NEW YORK, APRIL 20, 2026 /PRNEWSWIRE/ -- THE NEW YORK STOCK EXCHANGE (NYSE) PROVIDES A DAILY PRE-MARKET UPDATE DIRECTLY FROM THE NYSE TRADING FLOOR.

NYSE CONTENT UPDATE: SEC CHAIR PAUL ATKINS TO RING OPENING BELL AT NYSE

NEW YORK, APRIL 16, 2026 /PRNEWSWIRE/ -- COHEN & STEERS, INC. (NYSE:CNS) TODAY REPORTED ITS RESULTS FOR THE QUARTER ENDED MARCH 31, 2026. THE EARNINGS RELEASE ALONG WITH THE ACCOMPANYING EARNINGS PRESENTATION CAN BE VIEWED AT COHEN & STEERS REPORTS RESULTS FOR FIRST QUARTER 2026 AND ON THE COMPANY'S WEBSITE AT WWW.COHENANDSTEERS.COM UNDER "COMPANYINVESTOR RELATIONSEARNINGS ARCHIVE.

COHEN & STEERS REPORTS RESULTS FOR FIRST QUARTER 2026

NEW YORK, APRIL 14, 2026 /PRNEWSWIRE/ -- COHEN & STEERS, INC. (NYSE:CNS) TODAY ANNOUNCED A SERIES OF LEADERSHIP APPOINTMENTS AND ORGANIZATIONAL ENHANCEMENTS DESIGNED TO STRENGTHEN ITS U.S. WEALTH DISTRIBUTION CAPABILITIES AND SUPPORT CONTINUED GROWTH ACROSS KEY CLIENT SEGMENTS. BRAD ISPASS PROMOTED TO LEAD U.S. WEALTH BRAD ISPASS, FORMERLY HEAD OF ENTERPRISE WEALTH, HAS BEEN PROMOTED TO HEAD OF U.S. WEALTH, WHERE HE WILL LEAD THE FIRM'S DISTRIBUTION STRATEGY AND TEAMS ACROSS ALL U.S. INTERMEDIARY CHANNELS.

COHEN & STEERS ANNOUNCES U.S. WEALTH LEADERSHIP APPOINTMENTS

NEW TECHNOLOGY INTOX COLLECT HAS BEEN COMPLETED FOR COLLECTION AND ANALYSIS OF VOICE AND FACIAL RECOGNITION DATA USING AI FOR ALCOHOL AND A RANGE OF NEW SUBSTANCES THAT EFFECT THE CENTRAL NERVOUS SYSTEM. VANCOUVER, BRITISH COLUMBIA, APRIL 13, 2026 (GLOBE NEWSWIRE) -- MINDBIO THERAPEUTICS CORP. (CSE: MBIO; FRANKFURT: WF6; OTCQB: MBQIF), (THE COMPANY OR MINDBIO), A BIOTECHNOLOGY COMPANY COMMERCIALIZING AI-DRIVEN VOICE ANALYTICS FOR DRUG AND ALCOHOL INTOXICATION DETECTION, IS PLEASED TO ANNOUNCE THE COMPANY HAS COMPLETED THE DEVELOPMENT OF NEW TECHNOLOGY INTOX COLLECT WHICH HAS ENABLED THE COMPANY TO RAPIDLY SCALE ITS COLLECTION AND ANALYSIS OF DATA SAMPLES (INCLUDING VOICE AND FACIAL RECOGNITION DATA) FROM A WIDE RANGE OF SUBSTANCES WHEN CONSUMED.

MINDBIO DEPLOYS NEW TECHNOLOGY INTOX COLLECT; EXPANDS CNS DRUG DETECTION CAPABILITIES WITH VOICE & FACIAL RECOGNITION

NEW YORK, APRIL 9, 2026 /PRNEWSWIRE/ --COHEN & STEERS, INC. (NYSE:CNS) TODAY REPORTED PRELIMINARY ASSETS UNDER MANAGEMENT OF $93.1 BILLION AS OF MARCH 31, 2026, A DECREASE OF $5.3 BILLION FROM ASSETS UNDER MANAGEMENT OF $98.4 BILLION AT FEBRUARY 28, 2026. THE DECREASE WAS DUE TO MARKET DEPRECIATION OF $5.0 BILLION AND DISTRIBUTIONS OF $323 MILLION, PARTIALLY OFFSET BY NET INFLOWS OF $42 MILLION.

COHEN & STEERS ANNOUNCES PRELIMINARY ASSETS UNDER MANAGEMENT AND NET FLOWS FOR MARCH 2026

SEASONED BIOTECH EXECUTIVE BRINGS DEEP EXPERIENCE ACROSS CLINICAL DEVELOPMENT, REGULATORY STRATEGY, AND CORPORATE OPERATIONS, STRENGTHENING EXECUTION CAPABILITIES AS PLUS ADVANCES REYOBIQ AND CNS-FOCUSED PIPELINE SEASONED BIOTECH EXECUTIVE BRINGS DEEP EXPERIENCE ACROSS CLINICAL DEVELOPMENT, REGULATORY STRATEGY, AND CORPORATE OPERATIONS, STRENGTHENING EXECUTION CAPABILITIES AS PLUS ADVANCES REYOBIQ AND CNS-FOCUSED PIPELINE

PLUS THERAPEUTICS APPOINTS ERIC J. DANIELS, M.D.

NEW YORK, APRIL 8, 2026 /PRNEWSWIRE/ -- COHEN & STEERS, INC. (NYSE: CNS) ANNOUNCED THAT IT EXPECTS TO RELEASE FIRST QUARTER 2026 RESULTS AFTER THE MARKET CLOSES ON THURSDAY, APRIL 16, 2026. THE EARNINGS RELEASE AND ACCOMPANYING EARNINGS PRESENTATION WILL BE AVAILABLE ON THE COMPANY'S WEBSITE AT WWW.COHENANDSTEERS.COM UNDER "COMPANYINVESTOR RELATIONSEARNINGS ARCHIVE.

COHEN & STEERS, INC. TO RELEASE FIRST QUARTER 2026 RESULTS ON APRIL 16, 2026

NEW YORK, APRIL 08, 2026 (GLOBE NEWSWIRE) -- ATAIBECKLEY INC. (NASDAQ: ATAI) (ATAIBECKLEY OR COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ON A MISSION TO TRANSFORM PATIENT OUTCOMES BY DEVELOPING RAPID-ACTING, DURABLE AND CONVENIENT MENTAL HEALTH TREATMENTS, TODAY ANNOUNCED PEER-REVIEWED PHASE 2A RESULTS (NCT05660642) IN CNS DRUGS DEMONSTRATING THAT A SINGLE INTRANASAL DOSE OF BPL-003 (MEBUFOTENIN BENZOATE), WHICH HOLDS FDA BREAKTHROUGH THERAPY DESIGNATION, ACHIEVED RAPID AND SUSTAINED REDUCTIONS IN MADRS SCORES FROM BASELINE IN PARTICIPANTS WITH TREATMENT-RESISTANT DEPRESSION (TRD) WHO REMAINED ON STABLE SSRI THERAPY THROUGHOUT THE STUDY (N=12). A 66.7% ANTIDEPRESSANT RESPONSE RATE (50% REDUCTION FROM BASELINE MADRS SCORE) WAS OBSERVED AT DAY 2 IN BOTH THE 10 MG (N=6) AND 12 MG (N=6) COHORTS, WITH 83% (5/6) OF PARTICIPANTS IN THE 10 MG COHORT AND 66.7% (4/6) OF PARTICIPANTS IN THE 12 MG COHORT MAINTAINING A RESPONSE AT WEEK 12. BPL-003 WAS GENERALLY WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS REPORTED, AND PARTICIPANTS ACHIEVED A MEAN DISCHARGE APPROXIMATELY 100 MINUTES POST-DOSE. PHASE 3 STUDIES ARE ON TRACK TO INITIATE IN Q2 2026 FOLLOWINGRECENT FDA END-OF-PHASE 2 (EOP2) ALIGNMENT.

ATAIBECKLEY'S BPL-003 SHOWS RAPID, DURABLE ANTIDEPRESSANT RESPONSE IN TREATMENT-RESISTANT DEPRESSION PATIENTS ON SSRIS; PHASE 2A DATA PUBLISHED IN CNS DRUGS

NEW YORK, MARCH 30, 2026 /PRNEWSWIRE/ -- THIS PRESS RELEASE PROVIDES SHAREHOLDERS OF COHEN & STEERS CLOSED-END OPPORTUNITY FUND, INC. (NYSE:FOF) (THE "FUND") WITH INFORMATION REGARDING THE SOURCES OF THE DISTRIBUTION TO BE PAID ON MARCH 31, 2026 AND CUMULATIVE DISTRIBUTIONS PAID FISCAL YEAR-TO-DATE. IN DECEMBER 2021, THE FUND IMPLEMENTED A MANAGED DISTRIBUTION POLICY IN ACCORDANCE WITH EXEMPTIVE RELIEF ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.

NEW YORK, MARCH 30, 2026 /PRNEWSWIRE/ -- THIS PRESS RELEASE PROVIDES SHAREHOLDERS OF COHEN & STEERS TOTAL RETURN REALTY FUND, INC. (NYSE: RFI) (THE "FUND") WITH INFORMATION REGARDING THE SOURCES OF THE DISTRIBUTION TO BE PAID ON MARCH 31, 2026AND CUMULATIVE DISTRIBUTIONS PAID FISCAL YEAR-TO-DATE. IN DECEMBER 2011, THE FUND IMPLEMENTED A MANAGED DISTRIBUTION POLICY IN ACCORDANCE WITH EXEMPTIVE RELIEF ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.

NEW YORK, MARCH 30, 2026 /PRNEWSWIRE/ -- THIS PRESS RELEASE PROVIDES SHAREHOLDERS OF COHEN & STEERS REIT AND PREFERRED AND INCOME FUND, INC. (NYSE: RNP) (THE "FUND") WITH INFORMATION REGARDING THE SOURCES OF THE DISTRIBUTION TO BE PAID ON MARCH 31, 2026 AND CUMULATIVE DISTRIBUTIONS PAID FISCAL YEAR-TO-DATE. IN DECEMBER 2017, THE FUND IMPLEMENTED A MANAGED DISTRIBUTION POLICY IN ACCORDANCE WITH EXEMPTIVE RELIEF ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.

NEW YORK, MARCH 30, 2026 /PRNEWSWIRE/ -- THIS PRESS RELEASE PROVIDES SHAREHOLDERS OF COHEN & STEERS QUALITY INCOME REALTY FUND, INC. (NYSE: RQI) (THE "FUND") WITH INFORMATION REGARDING THE SOURCES OF THE DISTRIBUTION TO BE PAID ON MARCH 31, 2026 AND CUMULATIVE DISTRIBUTIONS PAID FISCAL YEAR-TO-DATE. IN DECEMBER 2012, THE FUND IMPLEMENTED A MANAGED DISTRIBUTION POLICY IN ACCORDANCE WITH EXEMPTIVE RELIEF ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.

NEW YORK, MARCH 30, 2026 /PRNEWSWIRE/ -- THIS PRESS RELEASE PROVIDES SHAREHOLDERS OF COHEN & STEERS INFRASTRUCTURE FUND, INC. (NYSE: UTF) (THE "FUND") WITH INFORMATION REGARDING THE SOURCES OF THE DISTRIBUTION TO BE PAID ON MARCH 31, 2026 AND CUMULATIVE DISTRIBUTIONS PAID FISCAL YEAR-TO-DATE. IN MARCH 2015, THE FUND IMPLEMENTED A MANAGED DISTRIBUTION POLICY IN ACCORDANCE WITH EXEMPTIVE RELIEF ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.

DALLAS--(BUSINESS WIRE)--LANTERN PHARMA AND STARLIGHT THERAPEUTICS ANNOUNCE FDA CLEARANCE OF IND FOR A PLANNED PHASE 1 PEDIATRIC CNS CANCER TRIAL OF STAR-001.

LANTERN PHARMA AND STARLIGHT THERAPEUTICS ANNOUNCE FDA CLEARANCE OF IND FOR A PLANNED PHASE 1 PEDIATRIC CNS CANCER TRIAL OF STAR-001

SACRAMENTO, CALIF., MARCH 26, 2026 /PRNEWSWIRE/ -- LUNAI BIOWORKS, INC. (NASDAQ: LNAI) TODAY ANNOUNCED IT HAS EXECUTED A BINDING $20 MILLION STRATEGIC TRANSACTION TO ACQUIRE BLOOD-BRAIN BARRIER (BBB) DELIVERY TECHNOLOGY AND CENTRAL NERVOUS SYSTEM (CNS) ALZHEIMER'S DRUG ASSETS FROM THE CLEMANN GROUP, SAS OR ITS ASSIGNEE.

LUNAI BIOWORKS EXECUTES $20M STRATEGIC TRANSACTION AT FIXED $1.50 CONVERSION, ACQUIRING BBB DELIVERY PLATFORM FOR CNS ALZHEIMER'S THERAPIES WITH BROAD CNS DELIVERY APPLICATIONS

NEW YORK, MARCH 24, 2026 /PRNEWSWIRE/ -- THE BOARD OF DIRECTORS OF THE COHEN & STEERS CLOSED-END FUNDS ANNOUNCED TODAY THE MONTHLY DISTRIBUTIONS FOR APRIL, MAY AND JUNE 2026, AS SUMMARIZED IN THE CHARTS BELOW: TICKER FUND NAME MONTHLYDIVIDEND FOF COHEN & STEERS CLOSED-END OPPORTUNITY FUND, INC. $0.087 LDP COHEN & STEERS LIMITED DURATION PREFERRED AND INCOME FUND, INC. $0.131 PSF COHEN & STEERS SELECT PREFERRED AND INCOME FUND, INC. $0.126 PTA COHEN & STEERS TAX-ADVANTAGED PREFERRED SECURITIES AND INCOME FUND $0.134 RFI COHEN & STEERS TOTAL RETURN REALTY FUND, INC. $0.080 RLTY COHEN & STEERS REAL ESTATE OPPORTUNITIES AND INCOME FUND $0.110 RNP COHEN & STEERS REIT AND PREFERRED AND INCOME FUND, INC. $0.136 RQI COHEN & STEERS QUALITY INCOME REALTY FUND, INC. $0.090 UTF COHEN & STEERS INFRASTRUCTURE FUND, INC. $0.165 DISTRIBUTIONS WILL BE MADE ON THE FOLLOWING SCHEDULE: MONTH EX-DIVIDEND/ RECORD DATE PAYABLE DATE APRIL APRIL 14, 2026 APRIL 30, 2026 MAY MAY 12, 2026 MAY 29, 2026 JUNE JUNE 9, 2026 JUNE 30, 2026 COHEN & STEERS INFRASTRUCTURE FUND, INC. HAS INCREASED ITS MONTHLY DISTRIBUTION BY $0.010 PER SHARE, TO $0.165 PER SHARE. THE FUND'S MONTHLY DISTRIBUTION HAS BEEN ADJUSTED TO REFLECT CURRENT MARKET CONDITIONS.

COHEN & STEERS CLOSED-END FUNDS DECLARE DISTRIBUTIONS FOR APRIL, MAY AND JUNE 2026

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)---- $ANRO #CNS--ALTO NEUROSCIENCE, INC. (ALTO) (NYSE: ANRO) A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL PRECISION MEDICINES FOR NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT MEMBERS OF THE COMPANY'S MANAGEMENT TEAM WILL PARTICIPATE IN A VIRTUAL FIRESIDE CHAT AT THE STIFEL 2026 VIRTUAL CNS FORUM ON MARCH 17, 2026 AT 12:00PM ET. THE PRESENTATION WILL BE ACCESSIBLE VIA A LIVE WEBCAST ON THE EVENTS AND PRESENTATIONS PAGE IN THE INVESTO.

ALTO NEUROSCIENCE ANNOUNCES PARTICIPATION AT THE STIFEL 2026 VIRTUAL CNS FORUM

SAN DIEGO--(BUSINESS WIRE)--ACADIA PHARMACEUTICALS INC. (NASDAQ: ACAD) TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE STIFEL 2026 VIRTUAL CNS FORUM ON TUESDAY, MARCH 17, 2026 AT 8:00 A.M. EASTERN TIME. A LIVE WEBCAST OF ACADIA'S FIRESIDE CHAT WILL BE ACCESSIBLE ON THE COMPANY'S WEBSITE, ACADIA.COM, UNDER THE INVESTORS SECTION AND AN ARCHIVED RECORDING WILL BE AVAILABLE ON THE WEBSITE FOR APPROXIMATELY ONE MONTH FOLLOWING THE PRESENTATION. ABOUT ACADIA PHARMACEUTICALS ACADIA.

ACADIA PHARMACEUTICALS TO PARTICIPATE IN THE STIFEL 2026 VIRTUAL CNS FORUM

WALTHAM, MASS.--(BUSINESS WIRE)--KORSANA BIOSCIENCES, INC. (KORSANA OR THE COMPANY), A BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING NOVEL THERAPIES TO REDUCE THE BURDEN OF NEURODEGENERATIVE DISEASES, TODAY ANNOUNCED THAT JONATHAN VIOLIN, PH.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THE STIFEL 2026 VIRTUAL CNS FORUM ON TUESDAY, MARCH 17, 2026 AT 3:00 PM ET. A LIVE WEBCAST OF THE COMPANY PRESENTATION WILL BE AVAILABLE ON THE COMPANY'S WEBSITE AT WWW.KORSANA.COM. A REPLAY.

KORSANA BIOSCIENCES TO PRESENT AT THE STIFEL 2026 VIRTUAL CNS FORUM

MIAMI & SEOUL, SOUTH KOREA--(BUSINESS WIRE)--LG CNS CO., LTD. AND PALANTIR TECHNOLOGIES INC. (NASDAQ: PLTR), A LEADING PROVIDER OF AI OPERATING SYSTEMS, TODAY ANNOUNCED A DEEPENED STRATEGIC PARTNERSHIP AIMED AT ACCELERATING AI TRANSFORMATION (AX) INITIATIVES ACROSS LG GROUP. THE ANNOUNCEMENT WAS MADE AHEAD OF PALANTIR'S AIPCON, WHERE THE TWO COMPANIES FORMALIZED THEIR JOINT AMBITION TO BRING TRANSFORMATIONAL BUSINESS IMPACT TO THE DIVERSE PORTFOLIO OF COMPANIES WITHIN ONE OF THE WORLD'S LARGEST.

LG CNS AND PALANTIR ANNOUNCE STRATEGIC PARTNERSHIP TO ACCELERATE AI TRANSFORMATION

NEW YORK, MARCH 11, 2026 /PRNEWSWIRE/ -- COHEN & STEERS, INC. (NYSE: CNS) TODAY ANNOUNCED PLANS TO CONVERT THE COHEN & STEERS FUTURE OF ENERGY FUND, A U.S. MUTUAL FUND DESIGNED TO CAPITALIZE ON OPPORTUNITIES ACROSS TRADITIONAL AND ALTERNATIVE ENERGY, INTO AN ACTIVELY MANAGED EXCHANGE-TRADED FUND ("ETF"). THE ETF WILL BE MANAGED BY THE SAME PORTFOLIO MANAGEMENT TEAM AND PURSUE THE SAME INVESTMENT OBJECTIVES AS THE CURRENT MUTUAL FUND.

COHEN & STEERS ANNOUNCES PLAN TO CONVERT THE COHEN & STEERS FUTURE OF ENERGY FUND TO ETF

NEWLY FORMED EXECUTIVE TEAM INITIATES GLOBAL SEARCH FOR DIFFERENTIATED THERAPEUTIC ASSETS FOR NEUROLOGY AND ONCOLOGY INDICATIONS, TWO OF BIOPHARMA'S LARGEST AND FASTEST-GROWING MARKETS STRATEGIC TRANSFORMATION DRIVEN BY A COMPREHENSIVE DATA ANALYSIS WILL ENABLE NEW EXECUTIVE TEAM TO LEVERAGE DECADES OF EXPERIENCE IN THESE THERAPEUTIC AREAS COMPANY PIVOTING FROM A SINGULAR FOCUS ON GLIOBLASTOMA AND WILL EXPLORE OUT-LICENSING OF LEGACY ASSETS BERUBICIN AND TPI 287 HOUSTON, TX / ACCESS NEWSWIRE / MARCH 11, 2026 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) (THE "COMPANY"), A BIOTECHNOLOGY COMPANY FOCUSED ON BUILDING A PIPELINE OF INNOVATIVE THERAPIES IN HIGH-VALUE NEUROLOGY AND ONCOLOGY MARKETS, TODAY ANNOUNCED THAT IT HAS LAUNCHED A NEW CORPORATE GROWTH STRATEGY DESIGNED TO BUILD A HIGH-VALUE PIPELINE IN NEUROLOGY AND ONCOLOGY. THE STRATEGY IS BEING LED BY THE NEWLY FORMED EXECUTIVE TEAM WITH DEEP EXPERIENCE ACROSS NEUROLOGY, ONCOLOGY AND RARE DISEASE DRUG DEVELOPMENT.

CNS PHARMACEUTICALS LAUNCHES NEW CORPORATE STRATEGY FOCUSED ON BUILDING A HIGH-VALUE NEUROLOGY AND ONCOLOGY PIPELINE

SARASOTA, FLA., MARCH 11, 2026 (GLOBE NEWSWIRE) -- ORAGENICS, INC. (NYSE AMERICAN: OGEN), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING BRAIN-TARGETED THERAPEUTICS THROUGH PROPRIETARY INTRANASAL DELIVERY TECHNOLOGY, TODAY ANNOUNCED THAT IT IS EXPLORING DISCUSSIONS WITH THIRD PARTIES REGARDING THE POTENTIAL ACQUISITION OF ADDITIONAL ASSETS IN THE CENTRAL NERVOUS SYSTEM (CNS) SPACE, WITH A SPECIFIC FOCUS ON BRAIN HEALTH AND BRAIN RECOVERY INDICATIONS THAT DEMONSTRATE STRATEGIC SYNERGIES WITH THE COMPANY'S LEAD CANDIDATE ONP-002 AND ITS PROPRIETARY INTRANASAL DRUG DELIVERY PLATFORM.

Cohen & Steers, Inc.

CNS

Price

Financial Reports

No items found.

Press Releases

Cohen & Steers, Inc.

CNS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CNS